Day One Biopharmaceuticals Inc. reported third quarter 2025 OJEMDA net product revenue of $38.5 million, a 15% increase from the previous quarter and up from $20.1 million in the third quarter of 2024. Year-to-date U.S. OJEMDA net product revenue reached $102.6 million, representing an 89% increase compared to the prior year. License revenue for the quarter was $1.3 million, compared to $73.7 million in the third quarter of 2024, which included upfront consideration from the sale of ex-U.S. commercial rights. Research and development expenses were $31.4 million, down from $33.6 million a year ago. Selling, general and administrative expenses totaled $28.1 million, compared to $29.0 million in the same period last year. The company reported a net loss of $19.7 million for the third quarter of 2025, compared to net income of $37.0 million in the third quarter of 2024. Cash, cash equivalents and short-term investments totaled $451.6 million as of September 30, 2025. Day One raised its full-year 2025 OJEMDA net product revenue guidance to $145 to $150 million and announced the upcoming presentation of three-year data from the FIREFLY-1 trial at the Society for Neuro-Oncology Annual Meeting.